Home › Geographic Atrophy
Geographic Atrophy clinical trials recruiting in the U.S.
24 studies for Geographic Atrophy are recruiting participants at sites across the United States.
Cities with the most studies
- Dallas, TX8 studies
- Reno, NV8 studies
- Santa Monica, CA7 studies
- Austin, TX7 studies
- Houston, TX6 studies
- Naperville, IL6 studies
- The Woodlands, TX6 studies
- Cleveland, OH6 studies
- Baltimore, MD6 studies
- Hagerstown, MD5 studies
- Erie, PA5 studies
- San Antonio, TX5 studies
- Sacramento, CA5 studies
- Washington, DC5 studies
- Spokane, WA5 studies
- St. Louis, MO5 studies
- Fort Worth, TX4 studies
- Nashville, TN4 studies
- Lynchburg, VA4 studies
- Raleigh, NC4 studies
- Philadelphia, PA4 studies
- St. Petersburg, FL4 studies
- Durham, NC4 studies
- Concord, CA3 studies
- Salt Lake City, UT3 studies
- Syracuse, NY3 studies
- Escondido, CA3 studies
- Abilene, TX3 studies
- Huntington Beach, CA3 studies
- Lewisville, TX3 studies
- San Francisco, CA3 studies
- Mountain View, CA3 studies
- Allentown, PA3 studies
- Phoenix, AZ3 studies
- Cincinnati, OH3 studies
- Los Angeles, CA3 studies
- Sarasota, FL3 studies
- Boston, MA3 studies
- Eugene, OR3 studies
- McAllen, TX3 studies
By state
- Arizona5 studies
- California13 studies
- Colorado4 studies
- Connecticut4 studies
- Florida8 studies
- Georgia4 studies
- Illinois9 studies
- Indiana3 studies
- Maryland7 studies
- Massachusetts7 studies
- Michigan5 studies
- Mississippi3 studies
- Missouri5 studies
- Nevada8 studies
- New Jersey3 studies
- New York4 studies
- North Carolina7 studies
- Ohio7 studies
- Oregon4 studies
- Pennsylvania9 studies
- South Carolina4 studies
- Tennessee4 studies
- Texas15 studies
- Utah4 studies
- Virginia4 studies
- Washington6 studies
Recently updated studies
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RecruitingPhase 1/2
Ages 55 to 95 · All sexes · Updated Sep 29, 2026 · NCT04339764A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RecruitingPhase 2
Ages 55 to 90 · All sexes · Updated Sep 23, 2026 · NCT06557460A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingPhase 1/2
Ages 55 and older · All sexes · Updated Sep 23, 2026 · NCT07029945A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RecruitingPhase 1/2
Ages 60 and older · All sexes · Updated Sep 22, 2026 · NCT07215234A Study in Adults With Geographic Atrophy
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Sep 21, 2026 · NCT07606365A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Sep 15, 2026 · NCT05626114A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RecruitingPhase 2/3
Ages 60 and older · All sexes · Updated Sep 14, 2026 · NCT06635148Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
Ages 55 and older · All sexes · Updated Sep 10, 2026 · NCT06659445A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RecruitingPhase 1
Ages 50 and older · All sexes · Updated Sep 3, 2026 · NCT03178149A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RecruitingObservational study
Ages 55 and older · All sexes · Updated Sep 3, 2026 · NCT07144137SGLT2 Inhibitors in Geographic Atrophy
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Aug 26, 2026 · NCT07174687Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Recruiting
Ages 60 and older · All sexes · Updated Aug 26, 2026 · NCT06662162A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
RecruitingPhase 2
Ages 55 and older · All sexes · Updated Aug 20, 2026 · NCT06659549Phase 1 Study of C.001 in Retinal Degeneration
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07594236Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
RecruitingPhase 1
Ages 50 and older · All sexes · Updated Aug 5, 2026 · NCT07230834Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingPhase 1/2
Ages 50 and older · All sexes · Updated Jul 13, 2026 · NCT07160179Stem Cell Ophthalmology Treatment Study II
Recruiting
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT03011541High Resolution Retinal Imaging
RecruitingObservational studyHealthy volunteers welcome
Ages 7 and older · All sexes · Updated May 5, 2026 · NCT01866371Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
RecruitingObservational study
Ages 55 and older · All sexes · Updated Apr 29, 2026 · NCT07556406Progression of Early Atrophic Lesions
RecruitingObservational study
Ages 50 and older · All sexes · Updated Mar 11, 2026 · NCT05959005A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
RecruitingPhase 1/2
Ages 50 to 85 · All sexes · Updated Jan 23, 2026 · NCT07158775A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Mar 24, 2025 · NCT06805474Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Recruiting
Ages 65 and older · All sexes · Updated Dec 3, 2024 · NCT05438732From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.